George Garibaldi

1.3k total citations
21 papers, 1000 citations indexed

About

George Garibaldi is a scholar working on Psychiatry and Mental health, Experimental and Cognitive Psychology and Molecular Biology. According to data from OpenAlex, George Garibaldi has authored 21 papers receiving a total of 1000 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Psychiatry and Mental health, 5 papers in Experimental and Cognitive Psychology and 4 papers in Molecular Biology. Recurrent topics in George Garibaldi's work include Schizophrenia research and treatment (12 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (3 papers) and Tryptophan and brain disorders (3 papers). George Garibaldi is often cited by papers focused on Schizophrenia research and treatment (12 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (3 papers) and Tryptophan and brain disorders (3 papers). George Garibaldi collaborates with scholars based in Switzerland, United Kingdom and United States. George Garibaldi's co-authors include Dragana Bugarski‐Kirola, Shitij Kapur, Carmen Galani Berardo, Stephen Z. Levine, Jonathan Rabinowitz, Stephen R. Marder, Celso Arango, Luca Santarelli, Daniel Umbricht and Thomas Blaettler and has published in prestigious journals such as Biological Psychiatry, Neuropsychopharmacology and Journal of Affective Disorders.

In The Last Decade

George Garibaldi

20 papers receiving 988 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
George Garibaldi Switzerland	12	559	249	221	195	164	21	1000
Dragana Bugarski‐Kirola United States	12	550 1.0×	242 1.0×	166 0.8×	177 0.9×	145 0.9×	30	878
Lena Flyckt Sweden	20	608 1.1×	226 0.9×	167 0.8×	216 1.1×	242 1.5×	50	1.2k
John R. Saksa United States	14	502 0.9×	265 1.1×	119 0.5×	147 0.8×	294 1.8×	17	1.2k
Don Goff United States	10	596 1.1×	471 1.9×	300 1.4×	161 0.8×	338 2.1×	13	1.3k
A. Elif Anıl Yağcıoğlu Türkiye	16	647 1.2×	127 0.5×	104 0.5×	126 0.6×	166 1.0×	59	976
Camilo de la Fuente‐Sandoval Mexico	21	571 1.0×	446 1.8×	152 0.7×	225 1.2×	622 3.8×	54	1.5k
Jeffery A. Lieberman United States	11	566 1.0×	360 1.4×	175 0.8×	133 0.7×	283 1.7×	14	1.1k
Satsuki Sumitani Japan	19	419 0.7×	267 1.1×	186 0.8×	119 0.6×	331 2.0×	40	1.1k
Yaël Ratner Israel	18	505 0.9×	86 0.3×	120 0.5×	165 0.8×	53 0.3×	26	995
Enrico Lattuada Italy	25	837 1.5×	571 2.3×	282 1.3×	253 1.3×	133 0.8×	44	1.6k

Countries citing papers authored by George Garibaldi

Since Specialization

Citations

This map shows the geographic impact of George Garibaldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George Garibaldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George Garibaldi more than expected).

Fields of papers citing papers by George Garibaldi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George Garibaldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George Garibaldi. The network helps show where George Garibaldi may publish in the future.

Co-authorship network of co-authors of George Garibaldi

This figure shows the co-authorship network connecting the top 25 collaborators of George Garibaldi. A scholar is included among the top collaborators of George Garibaldi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George Garibaldi. George Garibaldi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Omlor, Wolfgang, Tobias R. Spiller, Matthias Kirschner, et al.. (2025). Exploratory analysis of the relationship between striatal connectivity and apathy during phosphodiesterase 10 inhibition in schizophrenia: findings from a randomized crossover trial. BMC Medicine. 23(1). 187–187.

Bugarski‐Kirola, Dragana, Thomas Blaettler, Celso Arango, et al.. (2016). Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies. Biological Psychiatry. 82(1). 8–16. 109 indexed citations

Bugarski‐Kirola, Dragana, Nakao Iwata, Carol Reid, et al.. (2016). Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. The Lancet Psychiatry. 3(12). 1115–1128. 76 indexed citations

Nikolcheva, Tania, Robert Lasser, Susanne Ostrowitzki, et al.. (2016). CSF and amyloid pet biomarker data from scarlet road - a global Phase 3 study of gantenerumab in patients with prodromal AD. Neurobiology of Aging. 39. S28–S29. 3 indexed citations

Weiser, Mark & George Garibaldi. (2015). Quantifying motivational deficits and apathy: A review of the literature. European Neuropsychopharmacology. 25(8). 1060–1081. 20 indexed citations

Schooler, Nina R., Robert W. Buchanan, Thomas Laughren, et al.. (2015). Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms. Schizophrenia Research. 162(1-3). 169–174. 27 indexed citations

Scheltens, Philip, Tania Nikolcheva, Robert Lasser, et al.. (2015). DT‐01‐02: Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease. Alzheimer s & Dementia. 11(7S_Part_7). 7 indexed citations

Lasser, Robert, Chang-Heok Soh, G. Morrison, George Garibaldi, & Chris J. Edgar. (2015). O1‐10‐05: Identifying clinically relevant milestone decline in predementia Alzheimer's disease. Alzheimer s & Dementia. 11(7S_Part_3). 1 indexed citations

Cummings, Jeffrey L., Joseph H. Friedman, George Garibaldi, et al.. (2015). Apathy in Neurodegenerative Diseases. Journal of Geriatric Psychiatry and Neurology. 28(3). 159–173. 40 indexed citations

10.

Potkin, Steven G., Dragana Bugarski‐Kirola, Chris J. Edgar, et al.. (2014). Psychometric evaluation of the Work Readiness Questionnaire in schizophrenia. CNS Spectrums. 21(2). 199–206. 9 indexed citations

11.

Edgar, Chris J., et al.. (2014). Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms. Psychiatry Research. 218(1-2). 219–224. 26 indexed citations

12.

Calabrese, Joseph R., Maurizio Fava, George Garibaldi, et al.. (2014). Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. Journal of Affective Disorders. 168. 439–451. 49 indexed citations

13.

Arango, Celso, Henry A. Nasrallah, Stephen M. Lawrie, et al.. (2014). Efficacy and safety of adjunctive bitopertin (5 and 10mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the phase III DayLyte study. Schizophrenia Research. 158(1-3). e1–e1. 10 indexed citations

14.

Umbricht, Daniel, Richard S.E. Keefe, Stephen A. Murray, et al.. (2014). A Randomized, Placebo-Controlled Study Investigating the Nicotinic α7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia. Neuropsychopharmacology. 39(7). 1568–1577. 70 indexed citations

15.

Umbricht, Daniel, Daniela Alberati, Meret Martin‐Facklam, et al.. (2014). Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia. JAMA Psychiatry. 71(6). 637–637. 186 indexed citations

16.

Bugarski‐Kirola, Dragana, Celso Arango, W. Wolfgang Fleischhacker, et al.. (2014). EFFICACY AND SAFETY OF ADJUNCTIVE BITOPERTIN VERSUS PLACEBO IN SUBJECTS WITH PERSISTENT PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS – UPDATE FROM THE SEARCHLYTE PROGRAMME. Schizophrenia Research. 153. S20–S20. 5 indexed citations

17.

Arango, Celso, George Garibaldi, & Stephen R. Marder. (2013). Pharmacological approaches to treating negative symptoms: A review of clinical trials. Schizophrenia Research. 150(2-3). 346–352. 77 indexed citations

18.

Rabinowitz, Jonathan, Stephen Z. Levine, George Garibaldi, et al.. (2012). Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophrenia Research. 137(1-3). 147–150. 269 indexed citations

19.

Rabinowitz, Jonathan, George Garibaldi, Stephen Z. Levine, et al.. (2011). PMH56 Negative Symptoms Have Greater Impact on Functioning Than Positive Symptoms in Schizophrenia: Analysis of Catie Data. Value in Health. 14(7). A296–A297. 1 indexed citations

20.

Garibaldi, George, et al.. (1987). [Kawasaki's disease. 3 problems: incomplete clinical forms, steroid treatment, low doses of aspirin].. PubMed. 8(2). 233–41. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact